Humoral response profiling reveals pathways to prostate cancer progression.
about
Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cellsQuantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.Post genome-wide association studies functional characterization of prostate cancer risk loci.Glycoprotein analysis using protein microarrays and mass spectrometry.Immunogenicity of autoantigens.Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.Protein array patterning by diffusive gel stampingMass spectrometry of peptides and proteins from human blood.Prioritizing candidate disease metabolites based on global functional relationships between metabolites in the context of metabolic pathways.Autoantibody signatures: progress and perspectives for early cancer detectionMetastatic Melanoma Induced Metabolic Changes in C57BL/6J Mouse Stomach Measured by 1H NMR Spectroscopy.Serum Autoantibodies in Chronic Prostate Inflammation in Prostate Cancer Patients.Enhanced detection of autoantibodies on protein microarrays using a modified protein digestion techniqueThe fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry.New concepts in herpes simplex virus vaccine development: notes from the battlefield.Evaluation and characterization of anti-RalA autoantibody as a potential serum biomarker in human prostate cancer.Serum autoantibodies as biomarkers for early cancer detection.Identification of cancer autoantigens in serum: toward diagnostic/prognostic testing?Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins.Protein microarrays as an application for disease biomarkers.Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer.Imaging of branched chain amino acid metabolism in tumors with hyperpolarized 13C ketoisocaproate.Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejectionAutoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.Immunoprofiling using NAPPA protein microarrays.Osteopontin is a tumor autoantigen in prostate cancer patients.Influence of beta-galactose-specific mitochondrial lectins from prostate hyperplasic tissue on mitochondrial properties.
P2860
Q30528073-53778672-0ABD-4F47-A212-1798CFE13532Q33697764-A307B697-548D-4559-AB82-1F845CA8D7B4Q33702079-B23380C2-ABFA-4FCB-B009-FCCC99C038A8Q33927735-5D092708-4006-4F5A-AA78-5AFD2B356469Q33949907-F0FEF8F3-0407-403C-A502-6281294BCA79Q34049184-10A0D3E4-9B1E-472F-A287-17542C1FC338Q34447081-C913BB78-BC10-47B8-9381-F0FE1BD6E997Q35149802-28279FD3-4118-4224-AB83-E668C0D47A3FQ35231088-0CB03829-583E-4767-BF1E-11BF42DCF727Q35377236-C21769B2-B3BB-4863-B987-1613C10AC2F0Q35911466-80F3530F-4F90-4F1F-AB5C-8CF9C689E4DBQ35919544-EEC77EB3-5BA1-42B3-87B5-7469A4CA13DDQ37113624-2B00CE07-44D9-4AD8-94F5-891A37B0CF0EQ37286989-10DE7C2D-8C94-4E51-8BDB-F29D29718DD4Q37384857-564A8D5F-A49A-41A9-AAB4-2B6CB9FD7292Q37536632-7506A80E-1C98-4938-9E03-C24DE1F10B4FQ37622471-6CBDC975-D080-492A-A869-E3914C95AD15Q37766224-B02A04CB-E89C-40B1-A7C0-5FE0E0737B2AQ37790704-5466CFE2-6A78-4B30-9AAD-6214BCF5E03CQ38386585-C9267645-4968-4893-83E7-6ADB8D272D0EQ38559982-EA81AF84-D6F3-4A7F-952B-45C555D35786Q39658772-37983D39-B40E-4BBC-9735-228DC55F46F4Q39767017-60D047CD-01D1-4B31-AA5D-8F361EEE6B60Q39893150-5AF0B788-87F9-43D1-96C3-E908D957E4C7Q40747388-9FBC2E67-DAFC-4566-8B4F-09656A7F1EADQ41611585-5837D193-DE65-4199-9B58-01E8A41710C3Q41810965-A70FA6E2-59D2-48D7-840B-0A3530723983Q43237779-862B41FB-B1CA-4A67-ABFB-45B25771A9DF
P2860
Humoral response profiling reveals pathways to prostate cancer progression.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Humoral response profiling reveals pathways to prostate cancer progression.
@en
Humoral response profiling reveals pathways to prostate cancer progression.
@nl
type
label
Humoral response profiling reveals pathways to prostate cancer progression.
@en
Humoral response profiling reveals pathways to prostate cancer progression.
@nl
prefLabel
Humoral response profiling reveals pathways to prostate cancer progression.
@en
Humoral response profiling reveals pathways to prostate cancer progression.
@nl
P2093
P2860
P50
P1476
Humoral response profiling reveals pathways to prostate cancer progression.
@en
P2093
Anjana Menon
Arul M Chinnaiyan
Arun Sreekumar
Barry S Taylor
Bharathi Laxman
David M Lubman
Debashis Ghosh
Jianjun Yu
John T Wei
P2860
P304
P356
10.1074/MCP.M700263-MCP200
P577
2007-12-11T00:00:00Z